Clinical trials: Atopic Disorders
Atopic Dermatitis (AD), Non-atopic Healthy Controls
Atopic Dermatitis (AD) and Food Allergy
This is a prospective, single center, clinical mechanistic pilot clinical research study. Participants will not receive any investigational agent.
- Trial name
- NCT03168113
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
The Potential Role of Compounds Derived From Ultra-processed Foods in the Pathogenesis of Atopic Dermatitis in Pediatric Age
Atopic dermatitis (AD) is a common chronic inflammatory skin condition, primarily affecting children in urban and high-income areas.
- Trial name
- UPAD Project (NCT06996327)
- Testing
- Evaluation of dietary consumption of UPFs
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Atopic Dermatitis
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e.
- Trial name
- NCT00925730
- Testing
- Pimecrolimus
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis
Atopic Dermatitis
Text Messaging and Atopic Dermatitis
Atopic dermatitis is a common problem faced by patients of all ages and backgrounds. Treatment regimens and specific therapies may be time consuming and multiple studies have documented a parallel decrease in compliance as time…
- Trial name
- NCT01216059
- Testing
- Text message to cell phone
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
Rhinitis, Allergic
Mechanism of EGR2 in Allergic Rhinitis
EGR2 may be a target for the treatment of nasal polyps.
- Trial name
- NCT05724290
- Testing
- EGR2
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zu-xia Ma
Pregnancy Related, Allergy
Skin Barrier Assessment in Pregnancy and at Birth
This is a prospective birth cohort study assessing the role of maternal and environmental factors on the development of allergic diseases in children.
- Conditions
- Pregnancy Related, Allergy, Atopic Dermatitis Eczema, Asthma in Children
- Trial name
- NCT04445298
- Testing
- Transepidermal water loss, Skin tape stripping, Blood draw
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Atopic Dermatitis
Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates
Atopic dermatitis is a chronic disease, with outbreaks, predominant in childhood, whose main symptom is pruritus of variable intensity and signs of cutaneous xerosis and eczematous pattern lesions.
- Trial name
- LB2001 (NCT04271007)
- Testing
- Mometasone Furoate
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Libbs Farmacêutica LTDA
Atopic Dermatitis, Eczema Herpeticum
Registry for the Atopic Dermatitis Research Network
The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies.
- Trial name
- NCT01494142
- Where
- 9 sites in United States
- Volunteers
- 3,387 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
- Trial name
- NCT03058783
- Testing
- IDP-124 Lotion, IDP-124 Vehicle Lotion
- Where
- United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Neonatal Jaundice, Atopic Dermatitis
Skin Care Strategies for Neonatal Jaundice Phototherapy to Prevent Atopic Dermatitis in Moderate and Severe Infants
Atopic Dermatitis (AD) is a common chronic, recurrent, and inflammatory skin disease in children. The incidence of moderate to severe AD in infants aged 1-12 months in our country is as high as 25.41%, which is related to…
- Trial name
- NCT05178433
- Testing
- Use baby moisturizers by NeoChine
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai First Maternity and Infant Hospital
Atopic Dermatitis, Emollients
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients.
- Trial name
- AIMSI (NCT07358000)
- Testing
- Baume Relipid+
- Where
- France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Caen
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04936113
- Testing
- FB-401
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forte Biosciences, Inc.
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Immunotherapy, Allergy and Immunology
MAPS & ITEC Cohorts: 6-8 Years Follow-up
This study represents the follow-up, age 6-8 years, of children recruited at birth into two cohorts. The first cohort, the Mite Allergen Prevention Study (MAPS) was a double-blind, randomized controlled trial of the use of house…
- Conditions
- Immunotherapy, Allergy and Immunology, Asthma
- Trial name
- NCT03763630
- Testing
- House dust-mite SLIT, Normal saline
- Where
- 2 sites in United Kingdom
- Volunteers
- 263 people
- Sponsor
- University of Southampton
Atopic Dermatitis, Food Allergy
An Innovative Probiotic Product With Antiallergic Properties
Allergic diseases are currently one of the most important problem in medicine. Research confirms that probiotics administered during the formation of the intestinal ecosystem and the maturation of the immune system can positively…
- Conditions
- Atopic Dermatitis, Food Allergy, Effects of Probiotics
- Trial name
- NCT04738565
- Testing
- Probiotic preparation, Maltodextrin
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Children's Memorial Health Institute, Poland